About MABPRO, a.s.
Cancer immunotherapy platform for hypoxic tumors
Our company was established in year 2016 as a spin – off from the Biomedical Research Center of Slovak Academy of Sciences.
Advanced Patient Stratification
Tumor diagnostics
Pre-surgical biochemical and immunological analysis, post-surgical IHC analysis, RNA sequencing, and micro tumor preparation.
Analysis and machine learning
Collected data serve as a basis for individual characterization of tumors, including the genetic background, heterogeneity, and therapy sensitivity.
Effective therapy targeting
Identification of patients most likely to respond to our treatment is key to maximizing effectiveness and ensuring personalization.
Clinical and academic partners
A network of clinical sites working with experts in basic research, bioinformatics, and technology to support innovation and development.
Certificate
Development, production and distribution of biological organisms and materials, information, technology, intellectual property and standards for development, validation and application of scientific knowledge. Research and development in cancer immunotherapy.
Do you want to know more?
Personalized cancer immunotherapy for aggressive, hypoxic tumors with blockbuster potential
MABPRO, a.s. is building an immunotherapy platform and companion diagnostics for aggressive, hypoxic tumors using Carbonic Anhydrase IX (CA IX) as the therapeutic target and mechanism of action.
Extensive scientific literature, pre-clinical research and previous clinical studies confirm that targeting hypoxic tumors with CA IX can lead to highly effective immunotherapies for both solid and lymphomatic tumors.
Our Products Development Timeline
1
2016
Launching MABPRO, a.s.
MABPRO, a.s. holds an exclusive global license from BMC SAS for the CA IX patent portfolio, covering diagnostics, therapy, technology and know-how. The company is also licensed to develop new IP from the original rights, with full ownership of all resulting innovations and products.
2
2017 – 2018
MAB Humanization
MABPRO, a.s. has developed innovative biological drugs against CA IX, i.e. 25 humanized clones of murine monoclonal antibodies VII/20 and 25 humanized clones of murine monoclonal antibodies VII/18. It represents 50 variants of potential biological drugs.
3
2019
MAB Characterization
Characterization of 50 clones of humanized monoclonal antibodies (huMAbs) was done. Based on gained knowledge 2 huMabs has been chosen for further drug development process and commercialisation: CA9hu-1 and Ca9hu-2.
4
2019
Patent application
MABPRO is responsible for protecting the developed intellectual property. The unique sequences and properties of the CA9hu-1 and CA9hu-2 antibodies were included in the claims of two separate PCT patent applications. MABPRO, a.s. is the sole applicant in both cases. The applications were completed and filed under the Patent Cooperation Treaty (PCT) in 2019 and 2020, respectively.
5
2019
European Medical Agency
MABPRO, a.s. initiated pre-marketing authorisation procedures with the European Medicines Agency (EMA), including scientific advice and protocol assistance. As an EMA-registered SME, MABPRO benefits from a 90% fee reduction. The meeting was scheduled in Amsterdam for 30 September – 3 October 2019.
6
2023
SEAL of Excellence
Mabpro has been proudly recognised as a high-quality project proposal, standing out in a highly competitive evaluation process carried out by an international panel of independent experts. This recognition highlights the project’s excellence, innovation, and potential for significant impact.
Thank you for your support
